The effects of HIV protease inhibitors of carbohydrate and lipid metabolism

Current Infectious Disease Reports

Volumn 6, Issue 6, 2004, Pages 471-482

  Lee, Grace A ^a   Rao, Madhu N ^b   Grunfeld, Carl ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA INTERFERON; AMPRENAVIR; ATAZANAVIR; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NELFINAVIR; NEVIRAPINE; PIOGLITAZONE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIDOVUDINE;

CLINICAL TRIAL; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; GLUCONEOGENESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOINSULINEMIA; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER DYSFUNCTION; METABOLIC DISORDER; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; REVIEW; VOLUNTEER;

EID: 10244259281     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-004-0067-5     Document Type: Review

References (76)

1. Ferrannini E, Mari A: How to measure insulin sensitivity. J Hypertens 1998, 16:895-906.
2. Haugaard SB, Andersen O, Storgaard H, et al.: Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of non-glucose secretagogues and insulin resistance of beta-cells. Am J Physiol Endocrinol Metab 2004, 287: 677-685.
3. Woerle HJ, Mariuz PR, Meyer C, et al.: Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003, 52:918-925.
4. Hommes MJ, Romijn JA, Endert E, et al.: Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40:651-656.
5. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
6. Silva M, Skolnik PR, Gorbach SL, et al.: The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12:1645-1651.
7. Visnegarwala F, Krause KL, Musher DM: Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997, 127:947.
8. Dube MP, Johnson DL, Currier JS, Leedom JM: Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350: 13-714.
9. Behrens G, Dejam A, Schmidt H, et al.: Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
10. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 093-2099.
11. Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
12. Dube MP, Edmondson-Melancon H, Qian D, et al.: Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and b-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001, 27:130-134.
13. Dube MP, Qian D, Edmondson-Melancon H, et al.: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475-481.
14. Fisac C, Virgili N, Ferrer E, et al.: A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab 2003, 88:5186-5192.
15. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-F18.
16. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641-649.
17. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
18. Noor MA, Seneviratne T, Aweeka FT: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.
19. Noor MA: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
20. Shankar SS, Considine RV, Dube MP, Steinberg HO: Indinavir increases serum adiponectin in healthy HIV-negative men. Paper presented at the 63rd Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 13-17, 2003.
21. Lee GA, Mafong DD, Noor MA, et al.: HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004, 36:645-647.
22. Kinlaw WB, Marsh B: Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology 2004, 145:484-486.
23. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R: Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003, 8:9-15.
24. Sutinen J, Korsheninnikova E, Funahashi T, et al.: Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003, 88:1907-1910.
25. Tong Q, Sankale JL, Hadigan CM, et al.: Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003, 88:1559-1564.
26. Addy CL, Gavrila A, Tsiodras S, et al.: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003, 88:627-636.
27. Mynarcik DC, Combs T, McNurlan MA, et al.: Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002, 31:514-520.
28. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004, 140:786-794.
29. Xu A, Yin S, Wong L, et al.: Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004, 145: 87-494.
30. Nolte LA, Yarasheski KE, Kawanaka K, et al.: The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001, 50:1397-1401.
31. Murata H, Hruz PW, Mueckler M: Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002, 16:859-863.
32. Murata H, Hruz PW, Qiu H, Mueckler M: Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002, 51:937-942.
33. Rudich A, Vanounou S, Riesenberg K, et al.: The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001, 50: 425-1431.
34. Ranganathan S, Kern PA: The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol 2002, 172:155-162.
35. Koster JC, Remedi MS, Qiu H, et al.: HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003, 52:1695-1700.
36. Dufer M, Neye Y, Krippeit-Drews P, Drews G: Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol 2004, 369: 83-590.
37. Schwarz JM, Lee GA, Park S, et al.: Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004, 18:1852-1854.
38. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257-275.
39. Gelato MC, Mynarcik DC, Quick JL, et al.: Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002, 31:163-170.
40. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363: 29-438.
41. Mafong DD, Lee GA, Yu S, et al.: Development of multiplel lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy. AIDS 2004, 18:1742-1744.
42. Driscoll SD, Meininger GE, Lareau MT, et al.: Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004, 18:465-473.
43. Saint-Marc T, Touraine JL: Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy [letter]. AIDS 1999, 13:1000-1002.
44. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
45. Grunfeld C, Pang M, Doerrler W, et al.: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
46. Constans J, Pellegrin JL, Peuchant E, et al.: Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994, 24:416-420.
47. Feingold KR, Krauss RM, Pang M, et al.: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993, 76:1423-1427.
48. Grunfeld C, Kotler DP, Hamadeh R, et al.: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
49. Hellerstein MK, Grunfeld C, Wu K, et al.: Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993, 76:559-565.
50. Grunfeld C, Kotler DP, Shigenaga JK, et al.: Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991, 90: 54-162.
51. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
52. Sadler BM, Piliero PJ, Preston SL, et al.: Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001, 15:1009-1018.
53. Petit JM, Duong M, Florentin L, et al.: Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study. J Lipid Res 2003, 44:1692-1697.
54. Reeds DN, Mittendorfer B, Patterson BW, et al.: Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003, 285:E490-E497.
55. Liang JS, Distler O, Cooper DA, et al.: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001, 7:1327-1331.
56. Riddle TM, Kuhel DG, Woollett LA, et al.: HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001, 276:37514-37519.
57. Young B, Fischl MA, Wilson HM, et al.: Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 2002, 31:478-482.
58. Voigt E, Wasmuth JC, Vogel M, et al.: Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results. Infection 2004, 32: 2-88.
59. Badiou S, De Boever CM, Dupuy AM, et al.: Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen. AIDS 2003, 17: 72-774.
60. Torti C, Quiros-Roldan E, Regazzi-Bonora M, et al.: Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. J Acquir Immune Defic Syndr 2004, 35:324-326.
61. Murphy RL, Sanne I, Cahn P, et al.: Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003, 17:2603-2614.
62. Sanne I, Piliero P, Squires K, et al.: Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003, 32:18-29.
63. Squires K, Lazzarin A, Gatell JM, et al.: Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004, 36: 011-1019.
64. van der Valk M, Kastelein JJ, Murphy RL, et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001, 15: 407-2414.
65. Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700-705.
66. Martinez E, Domingo P, Galindo MJ, et al.: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004, 38:1017-1023.
67. Grunfeld C, Doerrler W, Pang M, et al.: Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997, 82:3734-3740.
68. Schmidt HH, Behrens G, Genschel J, et al.: Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther 1999, 4:163-170.
69. Behrens G, Schmidt HH, Stoll M, Schmidt RE: ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet 1999, 354:76.
70. Lister RK, Youle M, Nair DR, et al.: Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet 1999, 353:1678.
71. Fauvel J, Bonnet E, Ruidavets JB, et al.: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001, 15:2397-2406.
72. Miller J, Brown D, Amin J, et al.: A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002, 16: 195-2200.
73. Badiou S, Merle De Boever C, Dupuy AM, et al.: Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004, 172:273-279.
74. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
75. Fichtenbaum CJ, Gerber JG: Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002, 41:1195-1211.
76. Hsyu PH, Schultz-Smidi MD, Lillibridge JH, et al.: Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001, 45: 445-3450.